A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Business Overview Palatin™ is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (“MCR”) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 9.0M | 0 | 4.5M | - | - | - |
| Net Income | -9.6M | - | - | -24M | -36M | -34M |
| EPS | $-8.12 | $-32.15 | $-101.16 | $-110.50 | $-151.50 | $-180.81 |
| Free Cash Flow | 0 | -21M | -32M | -30M | -30M | -99K |
| ROIC | -43.0% | - | - | -142.9% | -80.1% | -67.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.00 | -10.08 | -1.16 | 0.02 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -9.8M | -17M | -22M | -32M | -37M | -33M |
| Operating Margin | -108.8% | - | -501.0% | - | - | - |
| ROE | -84.0% | - | - | - | -222.5% | -67.7% |
| Shares Outstanding | 2M | 1M | 1M | 0M | 0M | 0M |
PALATIN TECHNOLOGIES INC passes 0 of 9 quality checks, indicating weak fundamentals.
PALATIN TECHNOLOGIES INC (PTN) has a 5-year average return on invested capital (ROIC) of -96.9%. This is below average and may indicate limited pricing power.
PALATIN TECHNOLOGIES INC (PTN) has a market capitalization of $33M. It is classified as a small-cap stock.
PALATIN TECHNOLOGIES INC (PTN) does not currently pay a regular dividend.
PALATIN TECHNOLOGIES INC (PTN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PALATIN TECHNOLOGIES INC (PTN) generated $-21 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PALATIN TECHNOLOGIES INC (PTN) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
PALATIN TECHNOLOGIES INC (PTN) reported earnings per share (EPS) of $-32.15 in its most recent fiscal year.
The Ledger Terminal provides 16 years of financial data for PALATIN TECHNOLOGIES INC (PTN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PALATIN TECHNOLOGIES INC (PTN) has a book value per share of $-4.91, based on its most recent annual SEC filing.